With biosimilars makers eager to grab a piece of Humira's $12.5 billion-plus revenue, copies of AbbVie's blockbuster are on their way. What analysts disagree on, though, is when they'll arrive and how long it'll take them to make their presence known--and a pair of UBS analysts, for one, thinks the Illinois pharma has some marketing maneuvers up its sleeve to minimize their impact.
Big Pharma company AbbVie announced a €40 million investment in Ireland, aimed at increasing the production of drug delivery devices, such as a pen injector that is used to administer medications for autoimmune disorders.
AbbVie has walked away from its claim to Biotest's anti-CD4 monoclonal antibody, tregalizumab. The decision comes two months after Biotest posted Phase IIb data showing tregalizumab failed to outperform the placebo in terms of improvements to ACR20 scores.
AbbVie knows it has to press its case for Viekira Pak if it's going to get--and keep--a sizable share of the hepatitis C market. Today, it unveiled some new data that could help it do just that.
Flat news is good news. Pharma spending on advertising and promotional expenses will dip by just 1.7% next year, according to Schonfeld & Associates' annual Advertising Ratios & Budgets. That means a total of more than $21 billion in ad spending and just a bit healthier than last year's decline of 2%.
Here's something AbbVie doesn't want to hear: Industry watchers expect biosimilars for its top moneymaker Humira to be the most successful copycat biologics launched in the U.S. and Europe.
Gilead Sciences and AbbVie are quick to tout the efficacy of their hep C meds. Now, those numbers have helped the drugmakers score a win in the U.K. as the country's National Health Service (NHS) will spend £190 million ($294 million) for new treatments for the disease, including AbbVie's interferon-free treatment and Gilead's blockbuster hep C therapies.
U.S. payers are striking out at drug spending again, highlighting the cost to taxpayers. According to a commissioned report, 10 hot new "breakthrough" meds are expected to cost publicly funded healthcare plans more than $50 billion over the next decade.
Imbruvica partners Johnson & Johnson and AbbVie are counting on their blood cancer star Imbruvica to move up into earlier lines of chronic lymphocytic leukemia therapy, where the market potential is bigger. And now, they've got some trial data to support that move.
Halozyme Therapeutics' Enhanze tech platform essentially offers to take large molecules that would normally have to be delivered intravenously and make them available under the skin in a subcutaneous jab. And now AbbVie is jumping aboard, paying $23 million in an upfront and up to $130 million in milestones on each of up to 9 programs.